NASDAQ:TRML Tourmaline Bio (TRML) Stock Price, News & Analysis $16.81 +0.30 (+1.82%) Closing price 04:00 PM EasternExtended Trading$17.22 +0.41 (+2.43%) As of 05:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Tourmaline Bio Stock (NASDAQ:TRML) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Tourmaline Bio alerts:Sign Up Key Stats Today's Range$15.93▼$17.0450-Day Range$12.10▼$17.8552-Week Range$11.56▼$29.79Volume297,228 shsAverage Volume274,234 shsMarket Capitalization$431.76 millionP/E RatioN/ADividend YieldN/APrice Target$49.33Consensus RatingBuy Company OverviewTourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.Read More… Tourmaline Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks38th Percentile Overall ScoreTRML MarketRank™: Tourmaline Bio scored higher than 38% of companies evaluated by MarketBeat, and ranked 739th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingTourmaline Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageTourmaline Bio has only been the subject of 3 research reports in the past 90 days.Read more about Tourmaline Bio's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Tourmaline Bio are expected to decrease in the coming year, from ($3.02) to ($3.56) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tourmaline Bio is -5.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tourmaline Bio is -5.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTourmaline Bio has a P/B Ratio of 1.65. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Tourmaline Bio's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted19.91% of the float of Tourmaline Bio has been sold short.Short Interest Ratio / Days to CoverTourmaline Bio has a short interest ratio ("days to cover") of 9.4.Change versus previous monthShort interest in Tourmaline Bio has recently increased by 2.19%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTourmaline Bio does not currently pay a dividend.Dividend GrowthTourmaline Bio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted19.91% of the float of Tourmaline Bio has been sold short.Short Interest Ratio / Days to CoverTourmaline Bio has a short interest ratio ("days to cover") of 9.4.Change versus previous monthShort interest in Tourmaline Bio has recently increased by 2.19%, indicating that investor sentiment is decreasing. News and Social Media2.5 / 5News Sentiment0.50 News SentimentTourmaline Bio has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.88 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Tourmaline Bio this week, compared to 3 articles on an average week.MarketBeat Follows1 people have added Tourmaline Bio to their MarketBeat watchlist in the last 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Tourmaline Bio insiders have not sold or bought any company stock.Percentage Held by Insiders11.02% of the stock of Tourmaline Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions91.89% of the stock of Tourmaline Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Tourmaline Bio's insider trading history. Receive TRML Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tourmaline Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address TRML Stock News HeadlinesTourmaline Bio, Inc. (NASDAQ:TRML) Given Consensus Recommendation of "Buy" by BrokeragesMay 30 at 1:11 AM | americanbankingnews.comH.C. Wainwright maintains $50 target on Tourmaline Bio stockMay 29 at 10:37 AM | uk.investing.com3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are mere days away from a critical announcement from a key tech leader… One that will officially ignite “AI 2.0” – and potentially send a whole new class of stocks soaring. May 30, 2025 | Timothy Sykes (Ad)H.C. Wainwright Maintains Buy Rating on Tourmaline Bio (TRML) After Promising Phase 2 ResultsMay 29 at 10:37 AM | msn.comLeerink Partnrs Forecasts Tourmaline Bio FY2026 EarningsMay 27 at 2:13 AM | americanbankingnews.comBMO Sees Overreaction, Maintains Rating and Price Target on Tourmaline Bio (TRML)May 23, 2025 | msn.comTourmaline Bio posts mid-stage data for anti-inflammatory agentMay 21, 2025 | msn.comTourmaline Bio: TRANQUILITY Study Data Lends Credibility For IL-6 InhibitionMay 20, 2025 | seekingalpha.comSee More Headlines TRML Stock Analysis - Frequently Asked Questions How have TRML shares performed this year? Tourmaline Bio's stock was trading at $20.28 at the beginning of the year. Since then, TRML stock has decreased by 17.8% and is now trading at $16.68. View the best growth stocks for 2025 here. How were Tourmaline Bio's earnings last quarter? Tourmaline Bio, Inc. (NASDAQ:TRML) issued its quarterly earnings data on Friday, May, 2nd. The company reported ($0.89) EPS for the quarter, beating the consensus estimate of ($0.91) by $0.02. Who are Tourmaline Bio's major shareholders? Top institutional investors of Tourmaline Bio include QVT Financial LP (5.74%), Vanguard Group Inc. (4.64%), Octagon Capital Advisors LP (3.52%) and Nantahala Capital Management LLC (2.07%). Insiders that own company stock include Mark Mcdade, Parvinder Thiara and Sandeep Chidambar Kulkarni. View institutional ownership trends. How do I buy shares of Tourmaline Bio? Shares of TRML stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Tourmaline Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tourmaline Bio investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), TotalEnergies (TTE) and Southern First Bancshares (SFST). Company Calendar Last Earnings5/02/2025Today5/30/2025Next Earnings (Estimated)8/14/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TRML Previous SymbolNASDAQ:TRML CIK1827506 WebN/A Phone502-398-9250FaxN/AEmployees44Year FoundedN/APrice Target and Rating Average Stock Price Target$49.33 High Stock Price Target$70.00 Low Stock Price Target$25.00 Potential Upside/Downside+198.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($3.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$42.12 million Net MarginsN/A Pretax MarginN/A Return on Equity-20.97% Return on Assets-20.56% Debt Debt-to-Equity RatioN/A Current Ratio40.33 Quick Ratio40.33 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$10.08 per share Price / Book1.64Miscellaneous Outstanding Shares25,685,000Free Float22,817,000Market Cap$424.06 million OptionableOptionable Beta2.11 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:TRML) was last updated on 5/30/2025 by MarketBeat.com Staff From Our PartnersThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | SponsoredUrgent: Make this trade before you hit your pillow tonight… Most people waste 8 hours every night… And 227,916 hours in their lifetime… Dreaming about the life they...Timothy Sykes | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredHISTORIC Gold Move Sends Flashing Red Signal To 401K SaversHistorically, when panic hits Wall Street, investors rush to raise cash to cover their leveraged positions be ...Colonial Metals | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tourmaline Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tourmaline Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.